Nivolumab for NSCLC: five years on

Avelumab for metastatic Merkel cell carcinoma after chemotherapy

Nivolumab and ipilimumab combination for advanced skin cancer

Long-term clinical outcomes and analyses of atezolizumab for mTNBC

Checkmate 067 - combined nivolumab and ipilimumab

Durable responses to avelumab in patients with Merkel cell carcinoma

Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses

Five-year follow-up of nivolumab in NSCLC

Mechanisms of resistance in triple negative breast cancer

IMW 2017 highlights

Treatment of multiple myeloma patients in the relapsed setting: Expert discussion from IMW 2017

Multiple myeloma highlights from IMW 2017